More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$470916089
EPS
0.35
P/E ratio
--
Price to sales
2.58
Dividend yield
6.863%
Beta
0.8906
Previous close
$8.11
Today's open
$8.11
Day's range
$8.05 - $8.22
52 week range
$6.60 - $9.35
show more
CEO
Amir London
Employees
462
Headquarters
Rehovot,
Exchange
Nasdaq Global Select
Shares outstanding
57710305
Issue type
Common Stock
Healthcare
Pharmaceuticals
Kamada: Strong Growth, Improving Margins, Attractive Valuation, Upgrading To Buy
Kamada is upgraded to Buy, driven by strong KEDRAB demand, margin expansion, and raised 2026 guidance. KEDRAB maintains at least 50% U.S. market share, with robust demand expected to persist into 2027 and beyond. Distribution and biosimilars are rapidly expanding, targeting $20–$25 million revenue by 2030, diversifying KMDA's growth profile.
Seeking Alpha • Nov 13, 2026

Kamada Q3 Earnings Call Highlights
Kamada NASDAQ: KMDA raised its 2026 revenue and adjusted EBITDA guidance after reporting double-digit third-quarter growth, as demand increased for its KEDRAB rabies treatment and other products.
MarketBeat • Nov 9, 2026

Kamada Ltd. (KMDA) Q3 2026 Earnings Call Transcript
Kamada Ltd. (KMDA) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 9, 2026

Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year
REHOVOT, Israel and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
GlobeNewsWire • Nov 9, 2026

Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced financial results for the three months and nine months ended September 30, 2026, an increase of its 2026 annual guidance, and a dividend payment.
GlobeNewsWire • Nov 9, 2026

Kamada (KMDA) Surpasses Q3 Earnings Estimates
Kamada (KMDA) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago.
Zacks Investment Research • Nov 9, 2026

Kamada (KMDA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research • Nov 9, 2026

Ahead of Kamada (KMDA) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Kamada (KMDA) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks Investment Research • Nov 5, 2026

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026
REHOVOT, Israel and HOBOKEN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
GlobeNewsWire • Nov 2, 2026

Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026
REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
GlobeNewsWire • Oct 19, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Kamada Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.